Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
Aimee R HayesAlexander CrawfordKhulood Al RiyamiChristine TangJamshed BomanjiStephanie E BaldewegDamian WildDaniel MorgansteinAlice HarrySimona Grozinsky-GlasbergKira OleinikovBernard KhooMartyn E CaplinGuillaume P NicolasAshley B GrossmanPublished in: The Journal of clinical endocrinology and metabolism (2021)
The prevalence of high tumor avidity on 68Ga-DOTA-SSA PET/CT is low in the setting of metastatic MTC; nevertheless, PRRT may still be a viable treatment option in select patients.